Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci Corporation (Nasdaq: ABSI) announced its participation in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference. The virtual presentation is scheduled for September 20 at 2:00 p.m. PT / 5:00 p.m. ET. Attendees can access the live and archived webcast on Absci's website.
Absci utilizes deep learning and synthetic biology to enhance protein therapeutic potential through its Integrated Drug Creation™ Platform, aimed at discovering drug targets and optimal biotherapeutics efficiently.
Absci Corporation (Nasdaq: ABSI) reported its financial results for Q2 2021, showing a revenue of $0.7 million, up from $0.6 million in Q2 2020. The company recorded a significant net loss of $41.2 million, driven by increased R&D expenses of $11.0 million and SG&A expenses of $5.2 million. Key highlights include the acquisition of Totient, the completion of an IPO raising approximately $210 million, and the expansion of its workforce by over 100 employees. Absci also signed key agreements with PhaseBio and Alpha Cancer Technologies to advance its Integrated Drug Creation™ Platform.
Absci Corporation announced the closing of its initial public offering (IPO) on July 26, 2021, raising $230 million by selling 14,375,000 shares of common stock at $16.00 per share. The offering included full exercise of the underwriters' option for an additional 1,875,000 shares. Absci's stock began trading on the Nasdaq Global Select Market under the ticker symbol ABSI on July 22, 2021. Leading underwriters included J.P. Morgan, Credit Suisse, and BofA Securities.
Absci Corporation has announced the pricing of its initial public offering (IPO) of 12,500,000 shares at a price of $16.00 per share. The offering is expected to generate gross proceeds of $200.0 million, not including underwriters' options. Trading on the Nasdaq under the ticker symbol ABSI begins on July 22, 2021, with the offering closing anticipated on July 26, 2021, pending customary conditions. Notable managers for this IPO include J.P. Morgan, Credit Suisse, and others.
Absci Corporation has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock. The number of shares and price range are yet to be determined. Absci aims to list its stock on The Nasdaq Global Market under the symbol ABSI. Joint book running managers for the offering include J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel. This filing does not constitute an offer to sell securities prior to registration.